Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Classic Hodgkin Lymphoma (cHL), relapsed or refractory~* Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants \> 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.~* One prior anti-cancer therapy that did not work~Exclusion Criteria:~* Active, known, or suspected autoimmune disease or infection~* Active cerebral/meningeal disease related to the underlying malignancy~* More than one line of anti-cancer therapy or no treatment at all~* Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant~* Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Nivolumab + brentuximab vedotin (Type: EXPERIMENTAL): None
- brentuximab vedotin + bendamustine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).